Literature DB >> 17483987

Surgical options in undifferentiated thyroid carcinoma.

Brian Hung-Hin Lang1, Chung-Yau Lo.   

Abstract

Undifferentiated or anaplastic carcinoma is an uncommon histologic type of thyroid cancer. It is one of the most aggressive malignancies associated with a poor prognosis. Most patients are elderly presenting as locally advanced disease with nodal and distant metastases. Complete surgical resection is frequently not possible and there is no effective systemic therapy. Aggressive multimodal therapy including surgery, radiation, and chemotherapy is recommended for management. However, because of the rarity of the disease, its aggressiveness and the lack of prospective treatment protocols, nearly all evidence in the literature comes from retrospective case series or cohort studies for selected patients' subgroups treated over a relatively long study period. Evidence of therapeutic benefit of one treatment option over another is lacking. Prognosis remains dismal with a median survival of 2-12 months Surgery remains an important component of the multimodal therapy and is commonly adopted as primary treatment. Although radical resection should be discouraged, resection without inducing significant morbidity can be considered for good risk patients with resectable tumors. It provides an effective form of palliation with potential cure when combined with postoperative radiotherapy and/or chemotherapy. Patients selected for surgical resection was frequently identified to have improved survival. A regime of preoperative hyperfractionated radiotherapy and doxorubicin followed by surgery when feasible has been documented to achieve local control and avoid tracheostomy for ATC patients. Because of the ineffectiveness of all conventional treatment modalities, novel molecular targeted therapies are being developed to tackling this uniformly fatal disease with promising results.

Entities:  

Mesh:

Year:  2007        PMID: 17483987     DOI: 10.1007/s00268-007-0776-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  58 in total

1.  AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology.

Authors:  R H Cobin; H Gharib; D A Bergman; O H Clark; D S Cooper; G H Daniels; R A Dickey; D S Duick; J R Garber; I D Hay; J S Kukora; H M Lando; A B Schorr; M A Zeiger
Journal:  Endocr Pract       Date:  2001 May-Jun       Impact factor: 3.443

2.  Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy.

Authors:  E J Junor; J Paul; N S Reed
Journal:  Eur J Surg Oncol       Date:  1992-04       Impact factor: 4.424

3.  Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period.

Authors:  O Nilsson; J Lindeberg; J Zedenius; E Ekman; J Tennvall; H Blomgren; L Grimelius; G Lundell; G Wallin
Journal:  World J Surg       Date:  1998-07       Impact factor: 3.352

Review 4.  Poorly differentiated and anaplastic thyroid cancer.

Authors:  Kepal N Patel; Ashok R Shaha
Journal:  Cancer Control       Date:  2006-04       Impact factor: 3.302

5.  A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients.

Authors:  B Busnardo; O Daniele; M R Pelizzo; R Mazzarotto; D Nacamulli; D Devido; C Mian; M E Girelli
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

6.  Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases.

Authors:  Y S Venkatesh; N G Ordonez; P N Schultz; R C Hickey; H Goepfert; N A Samaan
Journal:  Cancer       Date:  1990-07-15       Impact factor: 6.860

7.  Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients.

Authors:  Nikola Besic; Marko Hocevar; Janez Zgajnar; Ana Pogacnik; Snjezana Grazio-Frkovic; Marija Auersperg
Journal:  Langenbecks Arch Surg       Date:  2004-12-15       Impact factor: 3.445

8.  Combination therapy for anaplastic giant cell thyroid carcinoma.

Authors:  M Schlumberger; C Parmentier; M J Delisle; J E Couette; J P Droz; D Sarrazin
Journal:  Cancer       Date:  1991-02-01       Impact factor: 6.860

9.  Anaplastic thyroid carcinoma: risk factors and outcome.

Authors:  J G Demeter; S A De Jong; A M Lawrence; E Paloyan
Journal:  Surgery       Date:  1991-12       Impact factor: 3.982

10.  Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery.

Authors:  J Tennvall; G Lundell; P Wahlberg; A Bergenfelz; L Grimelius; M Akerman; A-L Hjelm Skog; G Wallin
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

View more
  10 in total

1.  Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.

Authors:  Annette Wunderlich; Silvia Roth; Annette Ramaswamy; Brandon H Greene; Cornelia Brendel; Ulrike Hinterseher; Detlef K Bartsch; Sebastian Hoffmann
Journal:  Endocrine       Date:  2012-04-05       Impact factor: 3.633

Review 2.  Anaplastic thyroid cancer, tumorigenesis and therapy.

Authors:  J P O'Neill; D Power; C Condron; D Bouchier-Hayes; M Walsh
Journal:  Ir J Med Sci       Date:  2009-08-07       Impact factor: 1.568

3.  SEOM clinical guidelines for the treatment of thyroid cancer.

Authors:  Javier Martínez Trufero; Jaume Capdevilla; Juan Jesús Cruz; Dolores Isla
Journal:  Clin Transl Oncol       Date:  2011-08       Impact factor: 3.405

4.  Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival.

Authors:  Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-14       Impact factor: 2.503

Review 5.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

Review 6.  Current and Future Perspectives in Thyroid Carcinoma Treatment.

Authors:  José Manuel Gómez-Sáez
Journal:  Eur Endocrinol       Date:  2013-03-15

7.  A large nonmetastatic anaplastic thyroid cancer with complete thyroidal confinement.

Authors:  Jeffrey C Xing; Justin A Bishop; Nestoras Mathioudakis; Nishant Agrawal; Ralph P Tufano
Journal:  Case Rep Med       Date:  2011-09-07

Review 8.  The Role of Tracheostomy in Anaplastic Thyroid Carcinoma.

Authors:  Jia Xu; Zhen Liao; Jing-Jia Li; Xi-Fu Wu; Shi-Min Zhuang
Journal:  World J Oncol       Date:  2015-02-14

9.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  Scott N Pinchot; Rebecca S Sippel; Herbert Chen
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

10.  Individualised Multimodal Treatment Strategies for Anaplastic and Poorly Differentiated Thyroid Cancer.

Authors:  Sabine Wächter; Annette Wunderlich; Silvia Roth; Ioannis Mintziras; Elisabeth Maurer; Sebastian Hoffmann; Frederik A Verburg; Sebastian A Fellinger; Katharina Holzer; Detlef K Bartsch; Pietro Di Fazio
Journal:  J Clin Med       Date:  2018-05-15       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.